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MEDICATION MIGRATIONMEDICATION MIGRATIONEDICATION IGRATION
THE CHARLES TOWN NAPROXEN EXPERIENCE AND WHY IT MATTERS TO ALL 
RACING JURISDICTIONS
Therapeutic medications are critical to the health of humans and animals 
alike, and racehorses are no exception. To expect horses to perform at high 
levels without the benefit of modern therapeutic medication is both unrealistic 
and inhumane. All industry stakeholders agree that medication that impacts 
performance or masks lameness at the time of competition needs to be 
restricted, but turning back the clock to the time before we understood the 
benefits of anti-inflammatory medication in counteracting the rigors of high-
intensity performance is wrong for the industry as well as for the health and 
welfare of the horse.
Collateral damage from the aggressive push of industry regulators to limit 
the use of therapeutic medications has included the loss of any number of 
medications previously in common use. Among those medications with valuable 
applications in racehorses that have been unrealistically restricted  
are isoxsuprine, methocarbamol and naproxen. 
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GETTING TO KNOW 
NAPROXEN
For many years, Equiproxen 
was available as an FDA-approved, 
safe and effective nonsteroidal anti-
inflammatory (NSAID) for horses. 
Like humans, not all horses respond 
similarly to all NSAIDs, and the 
availability of different FDA-approved 
formulations allowed access of 
appropriate anti-inflammatories 
for horses in need of alternatives to 
phenylbutazone or flunixin. For that matter, 
while it has not been available to the market in a number of years, Equiproxen 
remains an FDA-approved medication for horses.
Despite Equiproxen’s lack of availability, veterinarians and horsemen 
alike have continued to use naproxen, the FDA-approved human formulation, 
for those horses in need of this alternative NSAID. In some jurisdictions, such 
as Kentucky, warnings have been issued to avoid such use because traces of 
naproxen can be detected for weeks after a relatively short course of treatment.
Naproxen is usually recommended for back pain and relief of muscle 
cramping in cases in which typical treatments like methocarbamol are 
ineffective alone.1 Additionally, naproxen is prescribed to horses with sore 
feet to avoid injections of the coffin joints and navicular bursae, procedures 
that concern practitioners when required repeatedly.2  To provide the best 
possible care for the high-level athletes under their care, veterinarians 
reach for naproxen in these specific instances in which other NSAIDs are not 
therapeutically effective.
LOGIC OF IDENTIFYING NAPROXEN AT  
LOW LEVELS
Naproxen can be identified in horses for up to 47 days after the last 
administration if the horse remains stabled in the same stall in which it was 
administered the medication (Wennerlund et al., 2000). More important, the 
amount of naproxen identified in a horse that was never given naproxen but 
stabled in the stall of a horse given naproxen can be indistinguishable from a 
horse actually given the drug. Although logic would dictate that the amount of 
medication that can be recycled in a horse from urine contamination  
 
1 Nick Metinnis, DVM, personal communication
2 Mark Cheney, DVM, personal communication
cannot impact a horse’s physiology in any way, these trace blood levels can be 
detected and may be called a positive in some jurisdictions. Common sense and 
logic occasionally seem absent from the regulation of horse racing.
HORSEMEN’S ALERT ABOUT NAPROXEN
The likelihood of environmental contamination from naproxen causing 
a positive test has not been lost on the National Horsemen’s Benevolent and 
Protective Association, and the following alert was published in its book, World 
Rules for Equine Drug Testing and Therapeutic Medication Regulation: 2012 
Policy of the National Horsemen’s Benevolent and Protective Association, by Dr. 
Thomas Tobin, Dr. Kimberley Brewer and Kent Stirling:
Naproxen is an oral medication. The dose is large, and naproxen seems to 
be chemically stable in the environment. Testing can be highly sensitive, and 
traces of naproxen have been detected for long periods after the last nominal 
administration, most likely associated with its environmental presence and 
resulting in inadvertent re-exposure. In April 2006, Kentucky recommended 
“horsemen, veterinarians and owners to discontinue use of naproxen AT LEAST 
120 hours before the race in which the horse is entered.”
Naproxen is a classic stall/environmental substance in the horse. It is a 
high-dose oral NSAID used in both humans and horses. The dose to a horse is 
5-10 mg/kg or more administered orally once or twice a day, so the total daily 
dose can be as high as 10 grams/day. By modern analytical standards, this is 
an amount that a chemist will trip over, making naproxen readily detectable 
in post-race plasma and urine samples. Additionally, naproxen is unusual in 
that it is a relatively small molecule; one gram of naproxen actually contains 
33 percent more naproxen molecules for the chemist to detect than one gram 
of phenylbutazone.
ATTENDANT WITH [THE CHANGE IN CONTRACT LABORATORY] WAS A SUDDEN 
SPORADIC PATTERN OF IDENTIFICATION OF LOW-CONCENTRATION NAPROXEN 
POSITIVES [AT CHARLES TOWN]. … WHERE WERE THESE LOW-CONCENTRATION 
PLASMA NAPROXEN IDENTIFICATIONS COMING FROM?
®
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INADVERTENT ENVIRONMENTAL EXPOSURE
The importance of inadvertent stall/environmental exposure as a source 
of trace-level identifications was abruptly brought to the attention of the 
racing world in Cambridge, England, in 2000, and naproxen was a charter 
member of this first group of identified stall-contaminating medications. At 
the International Conference of Racing Analysts and Veterinarians (ICRAV) that 
year, no fewer than four papers were presented showing that the therapeutic 
medications flunixin, naproxen, meclofenamic acid and isoxsuprine were all 
significant stall contaminants, to the extent that a clean horse put into a 
post-treatment stall immediately went “positive” just from exposure to the 
post-treatment stall environment. In a paper from Hong Kong, it was shown 
that cobwebs in a treatment stall contained the medication, immediately 
explaining a number of unexpected isoxsuprine identifications. Since that time, 
myriad papers in different journals have come to the same conclusion: Horses 
can trigger readily identifiable positive tests in post-race samples from urine 
contamination of their hay and bedding, even if the tested horse was never 
administered the medication.
In fact, looking back with the wisdom of hindsight, our Canadian 
colleagues had much earlier—around 1985 or so—seen the unusually 
long time required for horses to “clear” naproxen after the nominal last 
administration, showing that by 120 hours post-dosing plasma naproxen 
concentrations had bottomed out at about 200 ng/ml or so and then  
leveled out, not declining further. What was actually happening, of course, was 
that the naproxen in the stall was re-contaminating the horses, and what our 
Canadian colleagues were most likely measuring was evidence of the presence 
of naproxen in the stalls of these horses, as pointed out by our Swedish 
colleagues some 15 years later in their Cambridge 2000 ICRAV paper. 
NAPROXEN ISSUES AT CHARLES TOWN 
Fast-forward another 15 years to Charles Town Races in West Virginia 
in 2015, when Industrial Laboratories took over the state’s testing. When the 
Association of Racing Commissioners International’s Controlled Therapeutic 
Medication Schedule was introduced, the threshold for all substances not on 
the schedule went to zero tolerance, and the contract laboratory was changed 
from Truesdail to Industrial Laboratories. Attendant with this change was 
a sudden sporadic pattern of identification of low-concentration naproxen 
positives. They were being reported at a rate of about one a month in plasma, 
with concentrations ranging from 6 ng/ml to 160 ng/ml. The first question that 
springs to mind is this: Where were these low-concentration plasma naproxen 
identifications coming from?
Preliminary review of the data showed that one early plasma positive was 
at 4,000 ng/ml, fully consistent with a recent full dose naproxen administration. 
There were no further high-concentration naproxen identifications, suggesting 
a lesson learned. All of the other naproxen identifications, however, were much 
lower concentrations, the highest at 161 ng/ml and the balance below  
100 ng/ml, with most below 50 ng/ml and one as low as 6.3 ng/ml, a very low 
plasma concentration of naproxen.
An initial look at the low-concentration plasma identifications suggested 
that they were associated with “ship-ins,” so the first theory was that the ship-
in stalls at Charles Town were contaminated with naproxen. Responding to this 
possible explanation, the West Virginia Racing Commission reportedly sampled 
the ship-in stalls and had the samples analyzed, but to our knowledge the 
results of this testing have never been released.
We must also note that sampling a stall is one approach to this question 
but that a more relevant, definitive and defendable approach is to simply put a 
clean horse in the stall for a day or two and then take a blood and urine sample 
from the horse. As suggested by the considerable scientific literature on the 
subject, if the stall is actually significantly contaminated, the horse will test 
positive for the medication in question, and a horse sniffing around the stall in 
question for 24 to 48 hours is a much more definitive and defensible test than 
simply “spot sampling” the stall with samples that may or may not pick up 
what the horse will pick up and immediately transfer to his blood and urine.  
Our next step was to review all of the individually claimed naproxen 
identification information with the able assistance of Maria Catignani, 
executive director of the Charles Town HBPA. When working on the data files, 
we first looked at the jurisdictions from which the affected horse had shipped 
in to Charles Town. It soon became apparent that a preponderance of these 
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CONCLUSION
Rational thresholds for therapeutic medications need to be 
considered in all jurisdictions to allow the reasonable treatment 
of our precious athletes. The limitation of a practitioner’s 
armamentarium to an arbitrary 28 or 30 medications, with limited 
scientific basis for the thresholds, is at the very least unrealistic 
and at worst endangers the health and welfare of the horse. The 
West Virginia Racing Commission took the high road in the case of 
naproxen, choosing a reasonable threshold, and other jurisdictions 
should take notice. In a recent case in Kentucky, both the absolute 
insurer rule and the arbitrary threshold for methocarbamol were 
successfully challenged. Racing commissions across the country 
need to pay attention and follow the lead of West Virginia. Rational 
regulation of therapeutic medications avoids costly legal battles and 
allows our regulators to get back to the business of promoting horse 
racing and fighting the real threats to the integrity of our sport.
horse had shipped in from the Mid-Atlantic states, which, it also soon became 
apparent, had very different regulatory policies regarding naproxen compared to 
West Virginia’s. 
Based on discussions with veterinarians, chemists and other colleagues 
and a review of testimony in those Mid-Atlantic cases, it was found that many if 
not all of the Mid-Atlantic states have had a long-standing regulatory threshold 
for naproxen of 1,000 ng/ml in plasma, a threshold that is apparently still in 
place in these states.3
This finding immediately pointed to an additional possible source for these 
low-concentration plasma identifications of naproxen, namely that they were 
irrelevant trace-level residues of therapeutic administrations that “hung over” 
in horses racing in the Mid-Atlantic when they shipped in to Charles Town. 
None of these 161 ng/ml or less plasma residues identified in the Charles Town 
positives would have raised an eyebrow in the Mid-Atlantic states. Additionally, 
the range of values in these Charles Town ship-in identifications was 
sufficiently low enough that their origins could reasonably be attributed to trace 
residues of naproxen associated with inadvertent or unknowing stall exposure 
to traces of the medication. In lay terms, horses in the Mid-Atlantic states are 
racing with pharmacologically insignificant traces of naproxen in their plasmas. 
The concentrations are well below where the Mid-Atlantic drug testing radar is 
set for naproxen, but those concentrations have the potential to trigger a  
trace-level identification positive in the now zero tolerance for naproxen at 
Charles Town.
So, with regard to naproxen, it appears that Charles Town is a border 
jurisdiction with horses from the Mid-Atlantic shipping in that are clean by  
Mid-Atlantic levels but testing positive for traces of naproxen by Charles Town’s 
new regulatory standards. Given this circumstance, the most practical approach 
to this matter is to set a screening limit of detection for naproxen in Charles 
Town that recognizes that horses from the Mid-Atlantic states will occasionally 
tend to test above 6 ng/ml in plasma and to set an upper limit on this screening 
limit of detection that accommodates the needs of these Charles Town  
ship-in horses. 
3 George Maylin, DVM, personal communication
SETTING A SCREENING LIMIT FOR NAPROXEN
Taking this approach, we therefore reviewed the statistical spread of 
the trace-level Charles Town plasma identifications and calculated the 
concentrations at which “soft” and “hard” outliers of the trace-level naproxen 
identification population occurred. This analysis placed the “hard” outlier 
concentration at close to 250 ng/ml, which we selected as our recommended 
screening limit of detection for the Charles Town authorities in this naproxen 
matter.
We also reviewed how this proposed screening limit of detection compared 
with the current list of regulatory thresholds for the RCI-controlled therapeutic 
medication thresholds. Our analysis showed that this proposed screening limit 
of detection for naproxen fell within the broad range of the RCI-controlled 
therapeutic medication thresholds, confirming its suitability for use in 
circumstances such as the Charles Town situation.
A detailed copy of this analysis, with extensive supporting documentation 
and the proposed screening limit of detection solution, was presented to the 
West Virginia Racing Commission as it reviewed these naproxen identifications. 
The outcome was that a significant number of these identifications were 
rescinded, although it is unclear at this time precisely what the new screening 
limit of detection for naproxen in West Virginia is or will be.
That brings us to one final matter raised by these Charles Town events, 
which is the status—or more correctly at this time the non-status—of 
naproxen as an RCI-controlled therapeutic medication. Naproxen has a long 
international history and an excellent safety record as a controlled therapeutic 
medication as evidenced by the 1985 Canadian research and the 2000 Swedish 
research, as well as its 30-year history as a controlled therapeutic medication 
in the Mid-Atlantic states and its status as an FDA-approved medication in 
horses. Given these circumstances, it may well be appropriate to recommend 
to regulatory authorities outside of the Mid-Atlantic region that the decades-
long historical threshold for naproxen of 1 ug/ml be included in the RCI list of 
controlled therapeutic medications based on its long-established worldwide 
history of use as a safe and effective equine therapeutic medication.
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